A significant increase in efficiency was observed with the failed clinical candidate drisapersen, a 2′OMe-PS SSO that promotes dystrophin exon 51 exclusion as a treatment for Duchenne muscular dystrophy.32 The gene discussed is DMD; the disease is Duchenne muscular dystrophy.